Abstract 40P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality globally. Sorafenib remains the globally accepted systemic first-line treatment for advanced HCC patients. Due to the heterogeneity of HCC, patients usually develop drug resistance within six months. The underlying mechanisms of sorafenib resistance in HCC remain to be fully elucidated.
Methods
We established sorafenib-resistant HCC cell lines and characterized them using functional and microarray-based approaches. The subcellular localization of target proteins was determined by western blot analysis. Additionally, we generated an inducible system of constitutively active YAP1 mutant (YAP1-8SA) in Huh7. Furthermore, we utilized immunocompetent murine HCC model to evaluate the efficacy of galunisertib, sorafenib or their combination treatment.
Results
Sorafenib-resistant HCC cells exhibited higher IC50 values for sorafenib. Both Huh7 parental (Huh7-P) and sorafenib-resistant cells (Huh7-sorR) were selected for further analysis. Huh7-sorR demonstrated characteristics of EMT and de-differentiation, and both YAP1 and TGFβ1 signaling pathway were activated. Upon TGFβ1 stimulation in Huh7-P, the activation of YAP1 signaling pathway was observed. Similarly, constitutive YAP1 activation in Huh7-YAP8SA increased the protein level of TGFβ1. These results suggesting a positive feedback loop between YAP1 and TGFβ signaling pathways. The treatment of galunisertib suppressed the YAP1 signaling pathway in Huh7-sorR. Furthermore, the combination treatment of galunisertib and sorafenib greatly suppressed the growth of Huh7-sorR cells. In the in vivo study, the combination treatment of galunisertib and sorafenib also demonstrated prolonged overall survival.
Conclusions
We have identified YAP1-TGFβ1 axis as the underlying mechanism driving the sorafenib resistance in HCC. Our results showed that galunisertib could sensitize the resistant cells to sorafenib, by blocking the canonical TGFβ signaling pathway and its positive feedback to YAP pathway. TGFβ1 has been shown to be a potential biomarker for drug resistance and combination of sorafenib and galunisertib treatment would be an effective treatment regime for HCC recurrence patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
National Medical Research Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract